Baader Helvea is joining Vontobel and Zürcher Kantonalbank as the third research partner in the Stage Program, launched in September 2016. To date, eight companies have enjoyed the benefits of the program, which is designed to raise the visibility of listed companies in the market and with key stakeholders.
Baader Helvea, Vontobel and Zürcher Kantonalbank prepare research reports for offer small and medium-sized companies the possibility of receiving additional research coverage. This research coverage is offered as an add-on to the basic package, under which the listed company enjoys a regularly updated fact sheet provided by Morningstar, as well as training organized by SIX Swiss Exchange, and specific, target-group-relevant information and events.
Andrea von Bartenwerffer, Head Account Management Issuer Relations at SIX Swiss Exchange: "We are delighted to welcome another renowned research partner in the shape of Baader Helvea. The program has attracted a lot of interest from capital market participants since its launch. Eight companies are now reaping the benefits of the Stage program." Stefan Weber, CEO Newron Pharmaceuticals S.p.A, which participates in the program: "We welcome this initiative from SIX Swiss Exchange, which, in collaboration with its partners, is determined to counteract the decreasing research coverage of SMEs in recent years."
